

B. Remarks

Reconsideration is respectfully requested in view of the foregoing amendments and the following remarks.

Claims 1-2 have been cancelled without prejudice or disclaimer to the filing of a divisional application directed thereto.

Claim 3 has been amended. The amendments to the claims are supported by the as filed specification. The presently pending claims are 3-5, inclusive.

Claims 3-5 stand rejected under 35 U.S.C. § 102(b) as being anticipated by Le et al., U.S. Patent No. 5,698,195. This rejection is traversed.

Independent claim 3 has been amended to recite that the antibodies to TNF- α employed in the medicament have been highly diluted to form a mixture containing C50, C200 and C1000. These dilution levels are supported in Example 3.

The ultralow dilution levels for antibodies to TNF- α recited in independent claim 3, are not disclosed in the Le, et al. reference. Accordingly, the §102(b) reference has been overcome and should be withdrawn since the claims distinguish over the Le, et al. reference.

The issuance of a Notice of Allowance is solicited.

Please charge any fees which may be due to our Deposit Account No. 01-0035.

Respectfully submitted,

By: 

J. S. Cinamon
Registration No. 24,156
666 Third Avenue – 10th Fl.
New York, NY 10017-5621
(tel.) 212-949-9022
(fax) 212-949-9190